The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | David Maloney’s ASH 2019 CAR-T highlights
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, highlights the key updates in the CAR T-cell therapy field from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Dr Maloney specifically discusses the phase I study (NCT03338972) combining BCMA CAR T-cells with a small molecule gamma secretase inhibitor in multiple myeloma (MM). Additionally, Dr Maloney mentions a study of mosunetuzumab, a bispecific antibody, in lymphoma patients who have relapsed or are resistant to CAR-T therapy (GO29781; NCT02500407).
